Safety and efficiency of therapy by gene-engineering-biological preparations of rheumatoid arthritis
https://doi.org/10.21886/2219-8075-2018-9-3-44-49
Abstract
In this review of the literature, questions of the efficacy and safety of therapy with genetically engineered biological preparations for rheumatoid arthritis are discussed. The results of randomized trials of recent years are described in detail. Systematic literature search was conducted on the databases Scopus, Web of Science, MedLine, elibrary and others.
About the Author
E. A. Strel’tsov
Karaganda State Medical University, Karaganda
Kazakhstan
Evgeniy A. Strel’tsov, internal illnesses, intern doctor
Competing Interests: Конфликта интересов нет.
Kazakhstan
Evgeniy A. Strel’tsov, internal illnesses, intern doctor
Competing Interests: Конфликта интересов нет.
References
1. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023-2038. doi: 10.1016/S0140-6736(16)30173-8
2. Vriezekolk JE, van Lankveld WG, Geenen R, van den Ende CH. Longitudinal association between coping and psychological distress in rheumatoid arthritis: a systematic review. Ann Rheum Dis. 2011;70(7):1243-50. doi: 10.1136/ard.2010.143271
3. Rodríguez LA, Tolosa LB, Ruigomez A, Johansson S, Wallander MA. Rheumatoid arthritis in UK primary care: incidence and prior morbidity. Scand J Rheumatol. 2009;38(3):173-7. doi: 10.1080/03009740802448825
4. Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther. 2009;11(3):229. doi: 10.1186/ar2669
5. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376(9746):1094-108. doi: 10.1016/S0140-6736(10)60826-4
6. Huang CM, Chen HH, Chen DC, Huang YC, Liu SP, Lin YJ et all. Rheumatoid arthritis is associated with rs17337023 polymorphism and increased serum level of the EGFR protein. PLoS One. 2017;12(7):e0180604. doi: 10.1371/journal.pone.0180604
7. Lai CH, Lai MS, Lai KL, Chen HH, Chiu YM. Nationwide population-based epidemiologic study of rheumatoid arthritis in Taiwan. Clin Exp Rheumatol.2012;30(3):358–363
8. Kuo CF, Luo SF, See LC, Chou IJ, Chang HC, Yu KH. Rheumatoid arthritis prevalence, incidence, and mortality rates: a nationwide population study in Taiwan. Rheumatol Int. 2013;33(2):355-60. doi: 10.1007/s00296-012-2411-7
9. Zhu H, Xia W, Mo XB, Lin X, Qiu YH, Yi NJ et all. GeneBased Genome-Wide Association Analysis in European and Asian Populations Identified Novel Genes for Rheumatoid Arthritis. PLoS One. 2016;11(11):e0167212. doi: 10.1371/journal.pone.0167212
10. McGettrick HM, Butler LM, Buckley CD, Rainger GE, Nash GB. Tissue stroma as a regulator of leukocyte recruitment in inflammation. J Leukoc Biol. 2012;91(3):385-400. doi: 10.1189/jlb.0911458
11. Filer A, Ward LSC, Kemble S, Davies CS, Munir H, Rogers R et all. Identification of a transitional fibroblast function in very early rheumatoid arthritis. Ann Rheum Dis.2017;76(12):2105-2112. doi: 10.1136/annrheumdis-2017-211286
12. Guo ZY, Zhang JX, Wu M, Mei YF, Lin XJ, Bu C et all. Metaanalysis of the association between PADI4 -92C/G polymorphism and rheumatoid arthritis in the Chinese population. Braz J Med Biol Res. 2017;50(10):e6115. doi: 10.1590/1414-431X20176115
13. Luukkonen J, Pascual LM, Patlaka C, Lang P, Turunen S, Halleen J et all. Increased amount of phosphorylated proinfl ammatory osteopontin in rheumatoid arthritissynovia is associated to decreased tartrate-resistant acid phosphatase 5B/5A ratio. PLoS One. 2017;12(8):e0182904. doi: 10.1371/journal.pone.0182904
14. Loupasakis K, Kuo D, Sokhi UK, Sohn C, Syracuse B, Giannopoulou EG et all. Tumor Necrosis Factor dynamically regulates the mRNA stabilome in rheumatoid arthritisfibro blast-like synoviocytes. PLoS One. 2017;12(7):e0179762. doi: 10.1371/journal.pone.0179762
15. Bustamante MF, Garcia-Carbonell R, Whisenant KD, Guma M. Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther. 2017;19(1):110. doi: 10.1186/s13075-017-1303-3
16. Tanaka T, Narazaki M, Kishimoto T. Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. FEBS Lett. 2011;585(23):3699-709. doi: 10.1016/j.febslet.2011.03.023
17. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ et all. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69(1):88-96. doi: 10.1136/ard.2008.105197
18. Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Kelman A et all. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis. 2016;75(6):1081-91. doi: 10.1136/annrheumdis-2015-207628
19. Yamamoto K, Goto H, Hirao K, Nakajima A, Origasa H, Tanaka K et all. Longterm Safety of Tocilizumab: Results from 3 Years of Followup Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan. J Rheumatol. 2015;42(8):1368-75. doi: 10.3899/jrheum.141210
20. Schioppo T, Ingegnoli F. Current perspective on rituximab in rheumatic diseases. Drug Des Devel Ther.2017;11:2891-2904. doi: 10.2147/DDDT.S139248
21. Tak PP, Rigby W, Rubbert-Roth A, Peterfy C, van Vollenhoven RF, Stohl W et all. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis. 2012;71(3):351-7. doi: 10.1136/annrheumdis-2011-200170
22. Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, van Riel PL et all. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and lefl unomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. Ann Rheum Dis. 2012;71(3):374-7. doi: 10.1136/annrheumdis-2011-200003
23. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT et all. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(3):711-5
24. Hayashi S, Suzuki K, Yoshimoto K, Takeshita M, Kurasawa T, Yamaoka K et all. Early Prognostic Factors Associated with the Effi cacy of Infliximab Treatment for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate. Rheumatol Ther. 2016;3(1):155-166
25. Atteritano M, Mazzaferro S, Mantuano S, Bagnato GL, Bagnato G.F. Effects of infliximab on sister chromatid exchanges and chromosomal aberration in patients with rheumatoid arthritis. Cytotechnology. 2016;68(2):313-8. doi: 10.1007/s10616-014-9782-4
26. Th orne C, Bensen WG, Choquette D, Chow A, Khraishi M, Atkins CJ et all. Effectiveness and safety of infliximab in rheumatoid arthritis: analysis from a Canadian multicenter prospective observational registry. Arthritis Care Res (Hoboken).2014;66(8):1142-51. doi: 10.1002/acr.22290
27. Scott LJ. Etanercept: a review of its use in autoimmune inflammatory diseases. Drugs. 2014;74(12):1379-410. doi: 10.1007/s40265-014-0258-9
28. Bessette L, Khraishi M, Kivitz AJ, Kaliyaperumal A, Grantab R, Poulin-Costello M et all. Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment. Rheumatol Ther. 2017;4(2):391-404. doi: 10.1007/s40744-017-0079-x
29. Hobbs K, Deodhar A, Wang B, Bitman B, Nussbaum J, Chung J et all. Randomized, double-blind, placebo-controlled study to evaluate the effi cacy and safety of etanercept in patients with moderately active rheumatoid arthritis despite DMARD therapy. Springerplus. 2015;4:113. doi: 10.1186/s40064-015-0895-9
Review
For citations:
Strel’tsov E.A. Safety and efficiency of therapy by gene-engineering-biological preparations of rheumatoid arthritis. Medical Herald of the South of Russia. 2018;9(3):44-49. (In Russ.) https://doi.org/10.21886/2219-8075-2018-9-3-44-49
Views:
18412
Email this article 